President Donald Trump has announced a new agreement with pharmaceutical companies aimed at reforming drug pricing mechanisms. The agreement introduces varied pricing structures based on factors such as dose, product type, and the method of payment. This development is anticipated to have significant implications for patients, especially those with obesity, who may encounter different pricing tiers under the new framework.